STOCK TITAN

Bioxytran (BIXT) Stock News, Jul 2023-Jul 2024

BIXT OTC

Bioxytran, Inc. develops carbohydrate-based biotechnology programs focused on hypoxia, viral diseases, inflammation, metabolic health, and degenerative disease. News about BIXT commonly centers on ProLectin-M, its investigational oral antiviral candidate, including clinical study results, dose-optimization work, viral-clearance data, and regulatory-discussion updates for later-stage development.

Company updates also cover Bioxytran’s galectin-targeting platform, research collaborations involving polysaccharide and oligosaccharide interactions, and applications such as PHM23 in avian influenza research. Commercial news includes A-SUQAR®, a chewable dietary supplement containing a proprietary partially hydrolyzed guar gum formulation, along with distribution agreements and private-placement financing used for working capital and development programs.

Rhea-AI Summary

Bioxytran (OTCQB: BIXT) has formed a Joint Venture with the Heme Foundation to develop a Universal Oxygen Carrier (UOC) as an alternative to blood transfusions. The Foundation pledged up to $10 million for the project, with $2 million already invested in prototypes and compound development. Bioxytran retains all intellectual property rights, while the Foundation gains usage rights for blood transfusion applications.

The UOC, a hemoglobin-based oxygen carrier, is designed to be compatible with all blood types, pathogen-free, and shelf-stable at room temperature for 5+ years. It has shown promise in small-scale animal trials and is preparing for a large-scale toxicology study. This technology could revolutionize transfusion medicine, particularly in remote areas with blood supply infrastructure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
-
Rhea-AI Summary

Bioxytran's Science Advisor, Prof. Avraham Mayevsky, has published a book titled Hyperbaric Oxygenation Mitochondrial Activity and Brain Physiological Functions. The book, available as an eBook or hardcover from Springer, delves into the impact of hyperbaric oxygen on brain functions, particularly mitochondrial activity.

Central to the book is the MDX Viewer, an FDA-approved device that measures tissue oxygenation at the cellular level. The device's output, the Brain Metabolic Score (BMS), is essential for Bioxytran's acellular oxygen carrier (AOC) molecule, BXT-25, which is being developed for ischemic stroke and Alzheimer's disease treatments. Bioxytran aims to use BXT-25 to replace hyperbaric oxygen treatment (HBOT) in clinical trials.

The book offers a comprehensive overview of how hyperbaric oxygen impacts brain biochemical and physiological responses, influencing mitochondrial activity and enhancing brain functions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.90%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.47%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.08%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.05%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.23%
Tags
covid-19
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.00%
Tags
management

FAQ

What is the current stock price of Bioxytran (BIXT)?

Bioxytran (BIXT) last closed at $0.0230.

What is the market cap of Bioxytran (BIXT)?

The market cap of Bioxytran (BIXT) is approximately $2.6M.